Professor Chui is jointly appointed by the School of Nursing and School of Public Health at HKU. She obtained her PhD degree from the Department of Pharmacology and Pharmacy at HKU in 2017. She had led the design and analysis of studies using electronic health records from multi-databases (including Hong Kong, Taiwan, United Kingdom, Sweden, Australia and New Zealand). She was a visiting scholar (PhD exchange student) at the London School of Hygiene and Tropical Medicine in the United Kingdom. She completed her post-doctoral training in the School of Public Health at HKU in 2019.

Professor Chui aims to utilize Big Data from multi-regional/national large healthcare databases and that collected in the community to improve public health. Her current research focuses on cardiovascular disease risk prediction and evaluation using artificial intelligence (AI), Big Data for antimicrobial resistance surveillance, and improving care of people living with dementia. Professor Chui is a Co-principal investigator of AI and Pharmaceuticals in Non-Communicable Diseases at the Laboratory of Data Discovery for Health (D²4H). Professor Chui is also the convener and active member of NeuroGEN (Neurological and Mental Health Global Epidemiology Network), and one of the lead researchers in the CARE Programme, a comprehensive surveillance programme to monitor known and potential adverse events of COVID-19 vaccines.

She is the Principal investigator of a cardiovascular risk prediction model designed for Hong Kong population - P-CARDIAC (Personalised - CARdiovascular DIsease risk Assessment for Chinese) which her work is extensively covered by the media. Professor Chui has an h-index (Scopus) of 23 and has published more than 90 articles in peer-reviewed journals such as The Lancet Infectious Disease, Annals of Internal Medicine, BMJ, JAMA Internal Medicine, and Journal of the American College of Cardiology.

First author, co-first author*, co-/corresponding author#

1. Fan M, Wong SC, Yu Q, Li PH, Wu P, Chan EWY, Wong ICK, Tun HM, Cowling BJ, Cheng VC, Chui CSL#. Epidemiology and risk factors for Carbapenemase-Producing Enterobacteriaceae carriage in the hospital: a population-based nested case-control study. Journal of Global Antimicrobial Resistance. 2023 Apr 20:S2213-7165(23)00057-7. doi: 10.1016/j.jgar.2023.03.013. Epub ahead of print.
2. Fan M, Lai FTT, Cheng FWT, Tsie NTY, Li X, Wan EYF, Wong CKH, Chan EWY, Yiu KH, Wong ICK, Chui CSL#. Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a case–control study. Lancet Reg Health Western Pacific. 2023. doi: 10.1016/j.lanwpc.2023.100745.
3. Lai FTT, Fan M, Huang C, Chui CSL, Wan EYF, Li X, Wong CKH, Cheung CL, Wong ICK, Chan EWY. Effectiveness of BNT162b2 after extending the primary series dosing interval in children and adolescents aged 5-17. Nature Communications. 2023 Apr 3;14(1):1845. doi: 10.1038/s41467-023-37556-z.
4. Wan EYF, Yan VKC, Mok AHY, Wang B, Xu W, Cheng FWT, Lai FTT, Chui CSL, Li X, Wong CKH, Li PH, Cowling BJ, Hung IFN, Lau CS, Wong ICK, Chan EWY. Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 : A Target Trial Emulation Study. Annals of Internal Medicine. 2023 Apr;176(4):505-514. doi: 10.7326/M22-3057.
5. Lee H, Baek YH, Kim JH, Liao TC, Lau WCY, Man KKC, Qin X, Wood S, Ilomäki J, Bell JS, Lai EC, Leung MTY, Chan AYL, Chui CSL, Wong ICK, Shin JY. Trends of polypharmacy among older people in Asia, Australia and the United Kingdom: a multinational population-based study. Age and Ageing. 2023 Feb 1;52(2):afad014. doi: 10.1093/ageing/afad014.
6. Chui CSL*, Cheung KS, Brown JP, Douglas IJ, Wong ICK, Chan EW, Wong AYS. Proton pump inhibitors and myocardial infarction: an application of active comparators in a self-controlled case series. International Journal of Epidemiology. 2022 Oct 19:dyac196.
7. Wan EYF*, Chui CSL*, Ng VWS, Wang Y, Yan VKC, Lam ICH, Fan M, Lai FTT, Chan EWY, Li X, Wong CKH, Chung RKC, Cowling BJ, Fong WC, Lau AYL, Mok VCT, Chan FLF, Lee CK, Chan LST, Lo D, Lau KK, Hung IFN, Lau CS, Leung GM, Wong ICK. mRNA (BNT162b2) COVID-19 vaccination increased risk of Bell's palsy: a nested case control and self-controlled case series study. Clinical Infectious Diseases. 2022 Jun 8:ciac460. doi: 10.1093/cid/ciac460.
8. Chui CSL*, Fan M*, Wan EYF, Leung,MTY, Cheung E, Yan VKC, Gao L,  Ghebremichael-Weldeselassie Y, Man KKC, Lau KK, Lam ICH, Lai FTT, Li X, Wong CKH, Chan EW, Cheung CL, Sing CW, Lee CK, Hung IFN, Lau CS, Chan JYS, Lee MKY, Mok VCT, Siu CW, Chan LST, Cheung T, Chan FLF, Leung AYH, Cowling BJ, Leung GM, Wong ICK. Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination: a self-controlled case series study. EClinicalMedicine.2022 Jun 25;50:101504. doi: 10.1016/j.eclinm.2022.101504.
9. Wan EYF*, Chui CSL*, Wang Y, Ng VWS, Yan VKC, Lai FTT, Li X, Wong CKH, Chan EWY, Wong CSM, Leung KSM, Ni MY, Valkenburg SA, Peiris JSM, Wu JTK, Cowling BJ, Ashcroft DM, Hung IFN, Leung GM, Wong ICK. Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: A self-controlled case series and nested case-control study. The Lancet Regional Health-Western Pacific. 2022 Apr;21:100393. doi: 10.1016/j.lanwpc.2022.100393. Epub 2022 Feb 2.
10. Wan EYF*, Chui CSL*, Lai FTT, Chan EWY, Li X, Yan VKC, Gao L, Yu Q., Lam ICH, Chun RKC, Cowling BJ, Fong WC, Lau AYL, Mok VCT, Chan FLF, Lee CK, Chan LST, Lo D, Lau KK, Hung IFN, Leung GM, Wong ICK. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. The Lancet Infectious Diseases. 2022 Jan;22(1):64-72. doi: 10.1016/S1473-3099(21)00451-5. Epub 2021 Aug 16.